GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Champions Oncology Inc (NAS:CSBR) » Definitions » Net Income From Continuing Operations

CSBR (Champions Oncology) Net Income From Continuing Operations : $-3.40 Mil (TTM As of Jul. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Champions Oncology Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Champions Oncology's net income from continuing operations for the three months ended in Jul. 2024 was $1.31 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jul. 2024 was $-3.40 Mil.

Champions Oncology Net Income From Continuing Operations Historical Data

The historical data trend for Champions Oncology's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Champions Oncology Net Income From Continuing Operations Chart

Champions Oncology Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.09 0.36 0.55 -5.34 -7.28

Champions Oncology Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.57 -2.07 -2.53 -0.11 1.31

Champions Oncology Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Champions Oncology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Champions Oncology Inc (NAS:CSBR) » Definitions » Net Income From Continuing Operations
Comparable Companies
HRGN SYRS KZR CVM LVTX ATNM KRON AFMD MNPR IMRX VRTX REGN ASX:CSL XKRX:207940 XBRU:UCB ALNY XBRU:ARGX XKRX:068270 BNTX BGNE
Traded in Other Exchanges
2I3:Germany 2I3:Germany
Address
One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Website
https://www.championsoncology.com
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
Executives
Daniel Newman Mendelson director COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR, SUITE 900, BETHESDA MD 20817
Ronnie Morris director, officer: President 855 N. WOLFE STREET, SUITE 619, BALTIMORE MD 21205
Philip P. Breitfeld director ONE UNIVERSITY PLAZA, SUITE 307, HACKENSACK NJ 07601
New Enterprise Associates 14, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Neeraj Agrawal 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Roger H Lee 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Michael Maurice Brown 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Battery Management Corp. 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
R David Tabors 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Jesse Feldman 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Joel Ackerman director, officer: Chief Executive Officer COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR SUITE 900, BETHESDA MD 20817
Patrick J Kerins 10 percent owner
Ryan D Drant 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Harry R Weller 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815